New Drug Combination for Advanced Head and Neck Cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests two new cancer-fighting drugs together to treat advanced squamous cell carcinoma (a common type of head and neck cancer) in patients who cannot tolerate or refuse platinum-based chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with squamous cell carcinoma in your head or neck area (mouth, throat, or voice box)
- Your cancer has come back or spread after previous surgery, radiation, or other local treatment, and cannot be cured
- You are unable to tolerate platinum-based chemotherapy (like cisplatin) or choose not to receive it
- You are in good enough overall health (able to do light activities most days)
- Your blood counts, liver, and kidney function are within acceptable ranges
- You have not received systemic (body-wide) cancer treatment before, or it has been at least 6 months since your last treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests a new drug combo—becotatug vedotin plus a PD-1 inhibitor—for people with head and neck squamous cell cancer that cannot be surgically removed. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
Hear when a new HNPCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.